Key result
Standard guideline-directed HF therapies provide substantive clinical benefit and acceptable tolerability in elderly patients.
Why the study?
There have been very few prospective, placebo-controlled trials specifically in elderly heart-failure patients to determine the efficacy and tolerability of standard chronic heart-failure therapies.
Do standard chronic heart failure therapies improve mortality and morbidity in elderly patients with chronic heart failure?
Do standard chronic heart failure therapies improve mortality and morbidity in elderly patients with chronic heart failure?
Standard chronic heart failure therapies provide mortality and morbidity benefits in the elderly and should not be withheld due to age or fear of intolerance.
Answers are grounded in this paper and cite their sources.
Beta-blockers may benefit elderly HF patients; leaves open optimal regimens and combinations in frail subgroups.
PURPOSE OF REVIEW: beta-Blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, aldosterone receptor antagonists, and digoxin are the most common drug classes used to treat chronic heart failure. We examine current clinical trial evidence concerning heart-failure management in the elderly. RECENT FINDINGS: beta-Blockers provide significant mortality benefit to elderly heart-failure patients and are remarkably well tolerated. Angiotensin-converting-enzyme inhibitors improve mortality and morbidity in systolic heart failure. However, the risk/benefit relationship of angiotensin-converting-enzyme therapy in the elderly has not been adequately determined. Angiotensin II receptor blockers improve morbidity in elderly and non-elderly chronic heart-failure patients; however, data are limited regarding mortality in these patients. Aldosterone receptor antagonists provide significant mortality benefit to elderly chronic heart-failure patients. Digoxin is beneficial as an additive therapy in the treatment of systolic heart failure regardless of advanced age. SUMMARY: Agents that provide substantive clinical benefit overall also appear to do so in the elderly, based on subgroup analysis of major trials. There have been very few prospective, placebo-controlled trials specifically in elderly heart-failure patients. Elderly heart-failure patients generally tolerate standard chronic heart-failure therapies well. Standard chronic heart-failure therapies should not be withheld from elderly patients based on concerns regarding efficacy or fear of medication intolerance.
No takes yet. Share an insight, caveat, or question.
Dulin et al. (2006) conducted a review in Chronic heart failure in the elderly. Standard chronic heart-failure therapies (beta-blockers, ACE inhibitors, ARBs, aldosterone antagonists, digoxin) was evaluated. Standard chronic heart-failure therapies provide substantive clinical benefit and are well tolerated in elderly patients, based on subgroup analyses of major trials.
Synapse has enriched 10 related papers. Consider them for comparative context: